Latest News
Futura Medical reports positive home user test results for Eroxon and Intense variant
23 March 2026 - Consumer healthcare company Futura Medical plc (AIM: FUM) reported on Monday that it has recorded positive results from a Home User Test evaluating its marketed Eroxon product alongside a prototype formulation, Eroxon Intense, reinfor...
GSK secures Japan Orphan Drug status for lung cancer ADC
23 March 2026 - Pharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) declared on Monday that it has received Orphan Drug Designation in Japan for its investigational antibody-drug conjugate, risvutatug rezetecan, for the treatment of small-cell lung...
TheraCryf advances lead addiction programme to final preclinical stage
23 March 2026 - TheraCryf plc (AIM: TCF), a UK-based biotech company that develops new medicines for addiction and other neuropsychiatric disorders, announced on Monday that it has completed preclinical dose range finding studies for its lead orexin-...
Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment
23 March 2026 - Belief BioMed (BBM), a China-based global biotech company, announced on Monday that it has entered into an exclusive collaboration agreement with Grand Life Sciences Group Co Ltd, a pharmaceutical and healthcare enterprise group.Under...
Rhythm Pharmaceuticals selects PANTHERx Rare as exclusive US distribution partner for IMCIVREE expanded indication
23 March 2026 - PANTHERx Rare Pharmacy, a specialty pharmacy focused on rare and orphan diseases, announced on Friday that it has ben selected by biopharmaceutical company Rhythm Pharmaceuticals Inc (Nasdaq:RYTM) as the exclusive US pharmacy distribu...